InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
Drug
Haihe Pharma’s Glumetinib Gains Conditional NMPA Approval for NSCLC
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has received conditional market approval from...
JW Therapeutics Launches Carteyva Clinical Study for High-Risk Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
Haihe Pharma’s Glumetinib Receives Conditional Approval for NSCLC Treatment
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has obtained conditional market approval from...
JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...
AusperBio Initiates Phase I Trial for AHB-137 in New Zealand
Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...
BrightGene’s Generic Halaven Approved for Marketing in China
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...
Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...
Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the...
Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the...
Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...
Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study
China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully...
Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment
China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from...